The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.
about
Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VIIRegulation of glucose homeostasis by GLP-1Mechanisms of action of glucagon-like peptide 1 in the pancreasThe opioid effects of gluten exorphins: asymptomatic celiac diseaseDPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoformsPotential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus.Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.A proteolytic modification of AIM promotes its renal excretion.Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsThe role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidenceCharacterization of human myotubes from type 2 diabetic and nondiabetic subjects using complementary quantitative mass spectrometric methods.Müller glia as an important source of cytokines and inflammatory factors present in the gliotic retina during proliferative vitreoretinopathy.Enzymatic properties of dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis and its participation in virulence.Histopathological studies on virulence of dipeptidyl aminopeptidase IV (DPPIV) of Porphyromonas gingivalis in a mouse abscess model: use of a DPPIV-deficient mutant.Sodium butyrate has context-dependent actions on dipeptidyl peptidase-4 and other metabolic parameters.Molecular mechanism for connective tissue destruction by dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis.Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
P2860
Q24529863-562A2787-D9F7-4507-A20F-26A877119802Q24563430-CC179591-BE58-4EEF-AF4F-A4C8CFC60780Q24683764-91CD5711-DCC7-4325-927C-0FBBDF0655BBQ28077385-1CF8BC48-485B-4170-9659-36DF6EF33B42Q35161203-85B569EB-001A-4AC2-8255-605206FDAD51Q36072219-EBF4DF25-E412-4B66-8C61-13D7193757FEQ36136647-F09A8E65-3EC7-4AC1-AA41-1793928CD90CQ37033531-A0402C74-62E5-403E-AE2C-4043DDDABD7DQ37483757-D027CBFB-3123-4DD4-BE03-81A01A9FF2C6Q37725539-83689A66-DA57-4C21-85CF-AB7E04C4F43BQ38121545-49D86DF6-92AE-4ABC-85AE-EE85062E1AD6Q38619939-50AB5ECF-A7BE-4BF9-8635-87D002B4804FQ38820358-DAD6A14D-258D-41AA-BB2A-570DE0E2FC55Q39514087-DC9D1DB5-52CE-4678-BD2A-8AD4C69FD965Q39529738-9A0DC4CA-8320-42EF-86A5-D9458E135291Q41635922-4926E144-E0A2-4FF5-9C3D-615D220C3F02Q42175018-BECF7636-D566-4B33-9113-120DE3B47379Q42175983-F2E34626-8B96-4BA5-83E6-CD14027FC414
P2860
The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The unique properties of dipep ...... otential of DPP IV inhibitors.
@ast
The unique properties of dipep ...... otential of DPP IV inhibitors.
@en
type
label
The unique properties of dipep ...... otential of DPP IV inhibitors.
@ast
The unique properties of dipep ...... otential of DPP IV inhibitors.
@en
prefLabel
The unique properties of dipep ...... otential of DPP IV inhibitors.
@ast
The unique properties of dipep ...... otential of DPP IV inhibitors.
@en
P2093
P1476
The unique properties of dipep ...... potential of DPP IV inhibitors
@en
P2093
A M Lambeir
F Goossens
K Augustyns
W Bollaert
P304
P577
1999-04-01T00:00:00Z